**Tables**

**Table 1: Relative risks and odds ratios for DVT (symptomatic and asymptomatic), interventions compared with the reference treatment (no prophylaxis)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Intervention | Relative Risks (RRs) | | Odds Ratios (ORs) | |
| Direct  (mean with 95% confidence interval) | NMA (median with 95% credible interval) | Direct  (mean with 95% confidence interval) | NMA (median with 95% credible interval) |
| Versus no prophylaxis | LMWH (standard dose; standard duration) | 0.25 (0.11, 0.59) | 0.26 (0.15, 0.43) | 0.21 (0.08, 0.53) | 0.18 (0.10, 0.33) |
| LMWH (high dose; standard duration) | 0.29 (0.16, 0.52) | 0.18 (0.10, 0.30) | 0.15 (0.07, 0.34) | 0.12 (0.07, 0.22) |
| AES (length unspecified) | 0.58 (0.32, 1.07) | 0.88 (0.55, 1.56) | 0.52 (0.25, 1.07) | 0.83 (0.39, 1.80) |
| Dabigatran | 0.42 (0.29, 0.63) | 0.25 (0.14, 0.42) | 0.24 (0.13, 0.45) | 0.18 (0.10, 0.32) |
| IPCD (length unspecified) | 0.38 (0.18, 0.77) | 0.61 (0.32, 1.04) | 0.32 (0.14, 0.72) | 0.50 (0.23, 1.05) |
| Foot pump | 0.30 (0.13, 0.70) | 0.20 (0.05, 0.63) | 0.15 (0.04, 0.49) | 0.14 (0.03, 0.51) |
| Foot pump + AES | - | 0.55 (0.25, 1.48) | - | 0.44 (0.14, 1.65) |
| Rivaroxaban | - | 0.12 (0.06, 0.22) | - | 0.08 (0.04, 0.16) |
| Aspirin | - | 0.41 (0.16, 0.94) | - | 0.31 (0.11, 0.91) |
| LMWH (standard dose; extended duration) | - | 0.21 (0.08, 0.49) | - | 0.14 (0.05, 0.39) |
| Apixaban | - | 0.15 (0.07, 0.26) | - | 0.10 (0.05, 0.19) |
| VKA | - | 0.35 (0.17, 0.65) | - | 0.25 (0.11, 0.56) |
| UFH | - | 0.31 (0.13, 0.69) | - | 0.23 (0.09, 0.59) |
| Fondaparinux + AES | - | 0.35 (0.16, 0.67) | - | 0.26 (0.11, 0.59) |
| LMWH (standard dose; standard duration) + AES | - | 0.42 (0.24, 1.00) | - | 0.32, 0.11, 1.00) |
| LMWH (low dose; standard duration) + AES | - | 0.56 (0.26, 1.32) | - | 0.45 (0.15, 1.43) |
| LMWH high dose; standard duration) + AES | - | 0.77 (0.31, 1.57) | - | 0.68 (0.22, 2.00) |
| UFH + AES | - | 0.50 (0.19, 1.50) | - | 0.40 (0.10, 1.69) |

*LMWH: low-molecular-weight heparin, VKA: vitamin-K antagonist, UFH: unfractionated heparin, AES: anti-embolism stockings, IPCD: intermittent pneumatic compression device.* [*https://www.nice.org.uk/guidance/ng89*](https://www.nice.org.uk/guidance/ng89)

**Table 2: Relative risks and odds ratios for PE, interventions compared with the reference treatment (no prophylaxis)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Intervention | Relative Risks (RRs) | | Odds Ratios (ORs) | |
| Direct (mean with 95% confidence interval) | NMA (median with 95% credible interval) | Direct (mean with 95% confidence interval) | NMA (median with 95% credible interval) |
| Versus no prophylaxis | LMWH (standard dose; standard duration) | 0.33 (0.01, 8.09) | 0.20 (0.00, 8.57) | 0.33 (0.01, 8.20) | 0.19 (0.00, 9.16) |
| AES (length unspecified) | 1.00 (0.06, 15.79) | 0.98 (0.04, 24.95) | 1.00 (0.06, 16.19) | 0.98 (0.03, 25.61) |
| IPCD (length unspecified) | 0.33 (0.01, 8.09) | 0.20 (0.00, 8.53) | 0.33 (0.01, 8.20) | 0.19 (0.00, 9.08) |
| Dabigatran | - | 0.47 (0.00, 56.97)\* | - | 0.45 (0.00, 84.98)\* |
| Rivaroxaban | - | 0.08 (0.00, 6.65) | - | 0.08 (0.00, 7.24) |
| Apixaban | - | 0.52 (0.00, 36.43)\* | - | 0.50 (0.00, 46.20)\* |
| LMWH (standard duration; extended duration) | - | 0.02 (0.00, 3.86) | - | 0.01 (0.00, 4.19) |
| LMWH (standard dose; standard duration) + AES | - | 1.00 (0.01, 199.30)\* | - | 1.00 (0.01, 200.20)\* |
| LMWH (low dose; standard duration) + AES | - | 0.97 (0.01, 167.70)\* | - | 0.97 (0.00, 177.50)\* |
| LMWH (high dose; standard duration) | - | 0.37 (0.00, 30.66) | - | 0.36 (0.00, 39.32) |
| VKA | - | 0.63 (0.00, 64.93)\* | - | 0.61 (0.00, 92.15) |
| UFH | - | 1.79 (0.00, 625.00)\* | - | 1.99 (0.00, 5651.00)\* |

*LMWH: low-molecular-weight heparin, VKA: vitamin-K antagonist, UFH: unfractionated heparin, AES: anti-embolism stockings, IPCD: intermittent pneumatic compression device. .* [*https://www.nice.org.uk/guidance/ng89*](https://www.nice.org.uk/guidance/ng89)

*\* imprecisely estimated*

**Table 3: Odd ratios for major bleeding, interventions compared with the reference treatment (no prophylaxis/mechanical prophylaxis)**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Intervention | Direct (mean with 95% confidence interval) | NMA (median with 95% credible interval) |
| Versus no/ mechanical prophylaxis | LMWH (standard dose; standard duration) | 0.98 (0.28, 3.40) | 1.09 (0.34, 3.75) |
| LMWH (high dose; standard duration) | 0.32 (0.01, 8.08) | 1.02 (0.24, 3.97) |
| Fondaparinux | 1.04 (0.06, 16.84) | 6.74 (0.79, 76.28)\* |
| LMWH (low dose; standard duration) | 0.11 (0.01, 2.00) | 0.08 (0.00, 1.76) |
| Apixaban | - | 0.79 (0.18, 3.99) |
| Dabigatran | - | 1.08 (0.29, 4.36) |
| Rivaroxaban | - | 1.55 (0.32, 7.35) |
| LMWH (standard dose; extended duration) | - | 0.21 (0.00, 10.41)\* |
| UFH | - | 1.03 (0.07, 13.19)\* |
| VKA | - | 0.52 (0.08, 2.89) |

*LMWH: low-molecular-weight heparin, VKA: vitamin-K antagonist, UFH: unfractionated heparin, AES: anti-embolism stockings, IPCD: intermittent pneumatic compression device. .* [*https://www.nice.org.uk/guidance/ng89*](https://www.nice.org.uk/guidance/ng89)

*\*imprecisely estimated*